期刊文献+

嵌合抗原受体T细胞在恶性血液肿瘤的临床应用中的研究进展 被引量:5

Research progress on clinical application of chimeric antigen receptor t cells in blood malignancies
原文传递
导出
摘要 随着肿瘤免疫学理论和技术的发展,恶性血液肿瘤的治疗迎来新的纪元,过继性细胞免疫治疗(ACI)已成为研究热点.其中,利用嵌合抗原受体(CAR)修饰的T细胞治疗恶性血液肿瘤,在各项试验中均获得显著疗效.笔者拟就CAR-T细胞的构建及靶点选择,近年来与CAR-T细胞治疗相关的体内、外试验和临床研究,以及CAR-T细胞治疗目前尚待解决的问题进行综述. With the development of tumor immunological theory and technology,the treatment of blood malignancies is in a new era.Adoptive cellular immunotherapy (ACI) has become the hotspot of researches.Chimeric antigen receptor (CAR) modified T cell shows prominent therapeutic effect in various trails treating blood malignancies.In this paper,we describe the construction of CAR-T cell,choice of targets,clinical experiments related to CAR-T cell therapy in recent years,and the problems remain to be solved.
作者 曾萍 谭获
出处 《国际输血及血液学杂志》 CAS 2015年第1期69-72,共4页 International Journal of Blood Transfusion and Hematology
基金 广东省临床重点专科基金资助项目,Project No.20111219
关键词 抗原受体 血液肿瘤 细胞免疫治疗 过继 Receptors,antigen Hematologic neoplasms Cellular immunotherapy,adoptive
  • 相关文献

参考文献29

  • 1Hillerdal V,Ramachandran M,Leja J,et al.Systemictreatment with CAR-engineered T cells against PSCA delayssubcutaneous tumor growth and prolongs survival of mice[J].BMC Cancer,2014,14(1):30.
  • 2Ramos CA,Dotti G.Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy[J].Expert Opin Biol Ther,2011,11(7):855-873.
  • 3Cartellieri M,Bachmann M,Feldmann A,et al.Chimericantigen receptor-engineered T cells for immunotherapy of cancer[J].J Biomed Biotechnol,2010;956304.
  • 4Jensen MC,Riddell SR.Design and implementation of adoptivetherapy with chimeric antigen receptor-modified T cells[J].Immunol Rev,2014,257(1);127-144.
  • 5Jensen MC,Popplewell L,Cooper LJ,et al.Antitransgenerejection responses contribute to attenuated persistence ofadoptively transferred CD20/CDl9-specific chimeric antigenreceptor redirected T cells in humane[J].Biol Blood Marrow Transplant,2010,16(9):1245-1256.
  • 6Ma Q,Gomes EM,Lo AS,et al.Advanced generation anti-prostate specific membrane antigen designer T cells for prostatecancer immunotherapy[J].Prostate,2014,74(3):286-296.
  • 7Savoldo B,Ramos CA,Liu E,et al.CD28 costimulationimproves expansion and persistence of chimeric antigen receptormodified T cells in lymphoma patients[J].Clin Invest,2011,121(5):1822-1826.
  • 8Zhao Y,Wang QJ,Yang S,et al.A herceptin-based chimericantigen receptor with modified signaling domains leads toenhanced survival of transduced T lymphocytes and antitumoractivity[J].Immunol,2009,183(9):5563-5574.
  • 9Colovos Cf Villena-Vargas J,Adusumilli PS,et al.Safety andstability of retrovirally transduced chimeric antigen receptor Tcells[J].Immunotherapy,2012,4(9):899-902.
  • 10Dotti G,Gottschalk S,Savoldo B,Brenner MK.Design anddevelopment of therapies using chimeric antigen receptor-expressing T cells[J].Immunol Rev,2014,257(1):107-126.

同被引文献16

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部